CUV clinuvel pharmaceuticals limited

Ann: Appendix 4C - quarterly, page-4

  1. 982 Posts.
    lightbulb Created with Sketch. 533
    I like:

    - Increase of 121% on the March quarter 2019.
    - Financial year-end Cash Receipts to June 2019 of $32,221,000 wereup 36% compared to the prior financial year (to June 2018).
    - This indicates that more EPP patients in Europe arereceiving treatment with SCENESSE® and we look forward to the time the same treatment access can be provided toAmerican EPP patients who have no current alternatives.”
    - Net Cash from Operations was positive by $8,618,000 in the June quarter 2019. Net Cash from Operations for thetwelve months to 30 June 2019 was a positive $18,382,000 compared to a positive $11,693,000 in the same twelvemonth period to 30 June 2018.
    - Increasing cash balance - Cash Balance as at 30 June2019 increased to $54,269,000, compared to $44,975,000 as at 31 March 2019 and $36,198,000 as at 30 June 2018.

    Very positive outlook and building blocks foundation.

    Well done!
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$10.86
Change
0.090(0.84%)
Mkt cap ! $544.3M
Open High Low Value Volume
$10.60 $10.86 $10.54 $732.3K 68.44K

Buyers (Bids)

No. Vol. Price($)
1 1776 $10.68
 

Sellers (Offers)

Price($) Vol. No.
$10.95 100 1
View Market Depth
Last trade - 16.10pm 16/07/2025 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.